What smart money is saying about Oxford Nanopore
1 fund in our archive has pitched Oxford Nanopore — most recently Acatis in September 2026.
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Get an email when a fund writes about it
Position history
Between Q2 2025 and Q3 2026, 2 fund letters reported a position in Oxford Nanopore, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 1 |
| Q2 2025 | 1 | 0 | 0 | 0 |
Fund activity · 2 positions
- HoldsAcatisSeptember 2026
“The biggest ‚jumper‘ in this sense was AbCellera Biologics. Its share price doubled since the end of July. What was the reason? This Canadian company searches for antibo- dies. It came on our radar with a COVID-19 antibody, even though the antibody was qui- ckly invalidated because the virus is constantly mutating. On 10 August, AbCellera reported excellent Phase 2 data for an active ingredient to treat hot flashes during menopause. That was the trigger. What was the second-highest jump? Oxford Nanopore with a 55 percent gain.”
Oxford Nanopore - HoldsPlatinium AMJune 2025
“This quarter Biomerieux, a partner and equity holder of Oxford Nanopore (one of our holdings and up 33% for the quarter), announced a small acquisition of Day Zero Diagnostic.”
Oxford Nanopore
Fund coverage · 1 thesis
- AcatisSeptember 2026
Oxford Nanopore makes real-time DNA sequencing equipment with a consumables-driven model, growing sales, and narrowing losses.
Read the full thesis
Read every full thesis on Oxford Nanopore
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→